Contact Dr. Geoffrey K Isbister, Newcastle Mater Misericordiae Hospital, Locked Bag 7 Hunter Regional mail Centre, Australia.in the United States.maceuticals completed submission of the NDA for leukemia drugAriad provided the FDA with the rest of chemistry, manufacturing and controls, or CMC, ARIAD seeks U.S. Marketing approval Ponatinib in patients with resistant or intolerant chronic myeloid leukemia or CML and Philadelphia chromosome positive acute lymphoblastic leukemia or Ph+ ALL. The company has requested accelerated approval and priority review by of Ponatinib request of the FDA.
ARIAD expects approval and launch of Ponatinib in the U.S. In the first quarter of 2013. The Marketing Authorization Application for Ponatinib submitted in August, which has been validated by the European Medicines Agency , beginning its review of the application. The Committee for Human Medicinal Products ARIAD granted a request for accelerated examination of MAA.Letter in the latest issue of New England Journal of Medicine, writers KM Venkat Narayan, Muhammad Ali, and Jeffrey Koplan, claiming that the worldwide dissemination of chronic disorders also known as non-communicable diseases, offers a unique opportunity the low to find to find middle and high income around the globe in their efforts to concrete solutions to reduction of health and economic costs those diseases.